1. Home
  2. WHF vs ADCT Comparison

WHF vs ADCT Comparison

Compare WHF & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WhiteHorse Finance Inc.

WHF

WhiteHorse Finance Inc.

BUY

Current Price

$6.93

Market Cap

152.5M

Sector

Finance

ML Signal

BUY

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$1.42

Market Cap

136.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WHF
ADCT
Founded
2011
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.5M
136.1M
IPO Year
2012
2019

Fundamental Metrics

Financial Performance
Metric
WHF
ADCT
Price
$6.93
$1.42
Analyst Decision
Hold
Buy
Analyst Count
5
5
Target Price
★ $7.83
$3.33
AVG Volume (30 Days)
98.1K
★ 1.2M
Earning Date
11-09-2026
11-09-2026
Dividend Yield
★ 14.93%
N/A
EPS Growth
★ 31.91
30.86
EPS
★ 0.44
N/A
Revenue
N/A
★ $81,357,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.38
$26.43
P/E Ratio
$15.93
★ N/A
Revenue Growth
N/A
★ 14.85
52 Week Low
$6.07
$0.78
52 Week High
$7.84
$4.98

Technical Indicators

Market Signals
Indicator
WHF
ADCT
Relative Strength Index (RSI) 45.70 63.34
Support Level $6.87 $0.99
Resistance Level $7.22 $1.45
Average True Range (ATR) 0.19 0.10
MACD -0.03 0.02
Stochastic Oscillator 18.31 95.33

Price Performance

Historical Comparison
WHF
ADCT

About WHF WhiteHorse Finance Inc.

WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: